367 related articles for article (PubMed ID: 9532517)
1. Twenty-four-hour ambulatory blood pressure evaluation of antihypertensive agents.
Zanchetti A
J Hypertens Suppl; 1997 Dec; 15(7):S21-5. PubMed ID: 9532517
[TBL] [Abstract][Full Text] [Related]
2. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. Irbesartan Multicenter Investigators' Group.
Fogari R; Ambrosoli S; Corradi L; Degli Esposti E; Mos L; Nami R; Nicrosini F; Pessina AC; Salvetti A; Vaccarella A; Zanchetti A; Martin A; Reeves RA
J Hypertens; 1997 Dec; 15(12 Pt 1):1511-8. PubMed ID: 9431859
[TBL] [Abstract][Full Text] [Related]
3. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
Palatini P; Jung W; Shlyakhto E; Botha J; Bush C; Keefe DL
J Hum Hypertens; 2010 Feb; 24(2):93-103. PubMed ID: 19458624
[TBL] [Abstract][Full Text] [Related]
4. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.
Pechère-Bertschi A; Nussberger J; Decosterd L; Armagnac C; Sissmann J; Bouroudian M; Brunner HR; Burnier M
J Hypertens; 1998 Mar; 16(3):385-93. PubMed ID: 9557932
[TBL] [Abstract][Full Text] [Related]
5. Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension.
Coca A; Calvo C; Sobrino J; Gómez E; López-Paz JE; Sierra C; Bragulat E; de la Sierra A
Clin Ther; 2003 Nov; 25(11):2849-64. PubMed ID: 14693309
[TBL] [Abstract][Full Text] [Related]
6. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan.
Mancia G; Korlipara K; van Rossum P; Villa G; Silvert B
Blood Press Monit; 2002 Apr; 7(2):135-42. PubMed ID: 12048432
[TBL] [Abstract][Full Text] [Related]
7. The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group.
Howe P; Phillips P; Saini R; Kassler-Taub K
Clin Exp Hypertens; 1999 Nov; 21(8):1373-96. PubMed ID: 10574419
[TBL] [Abstract][Full Text] [Related]
8. Controlling blood pressure throughout the day: issues in testing a new anti-hypertensive agent.
Weber MA; Neutel JM; Smith DH
J Hum Hypertens; 1995 Nov; 9 Suppl 5():S29-35. PubMed ID: 8583478
[TBL] [Abstract][Full Text] [Related]
9. Blood pressure effects of the angiotensin II receptor blocker, losartan.
Weber MA; Byyny RL; Pratt JH; Faison EP; Snavely DB; Goldberg AI; Nelson EB
Arch Intern Med; 1995 Feb; 155(4):405-11. PubMed ID: 7848024
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of the effect of an angiotensin II receptor blocker SR47436 (irbesartan) on 24-hour blood pressure in patients with essential hypertension.
Kawano Y; Sato Y; Yoshinaga K
Hypertens Res; 2008 Sep; 31(9):1753-63. PubMed ID: 18971554
[TBL] [Abstract][Full Text] [Related]
12. [Antihypertensive effect of valsartan 80 mg and hydrochlorothiazide 12.5 mg evaluated by ambulatory blood pressure monitoring].
Vaïsse B; Ghobrial H; Vaur L; Poncelet P; Asmar R; Herpin D; Mallion JM
Arch Mal Coeur Vaiss; 2001 Aug; 94(8):907-12. PubMed ID: 11575229
[TBL] [Abstract][Full Text] [Related]
13. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
Ruilope L
J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516
[TBL] [Abstract][Full Text] [Related]
14. Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study.
De Rosa ML; de Cristofaro A; Rossi M; Baiano A; Cardace P; Albanese L; Vigorito C
J Cardiovasc Pharmacol; 2001 Sep; 38(3):482-9. PubMed ID: 11486253
[TBL] [Abstract][Full Text] [Related]
15. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
White WB; Lacourciere Y; Davidai G
Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
[TBL] [Abstract][Full Text] [Related]
16. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive efficacy of the angiotensin II AT1-receptor antagonist losartan: results of a randomized, double-blind, placebo-controlled, parallel-group trial using 24-hour blood pressure monitoring. Ambulatory Blood Pressure Monitoring Study Group.
Byyny RL
Blood Press Suppl; 1996; 2():71-7. PubMed ID: 8913544
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients.
de la Sierra A; Gil-Extremera B; Calvo C; Campo C; García-Puig J; Márquez E; Oliván J; Roca Cusachs A; Sanz de Castro S; Pontes C; Delgadillo J
J Hum Hypertens; 2004 Mar; 18(3):215-22. PubMed ID: 14973517
[TBL] [Abstract][Full Text] [Related]
19. Clinical overview of irbesartan: expanding the therapeutic window in hypertension.
Man in't Veld AJ
J Hypertens Suppl; 1997 Dec; 15(7):S27-33. PubMed ID: 9532518
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the effects of fixed dose vs. single-agent combinations on 24-h blood pressure variability.
Ulusoy S; Ozkan G; Konca C; Kaynar K
Hypertens Res; 2012 Nov; 35(11):1111-7. PubMed ID: 22786565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
